Miguel J. Lanz, MD, FAAAAI, FACAAI

Physician
Lanz Allergy, Asthma & Immunology
AAADRS Clinical Research Center
Doctors Hospital
Nicklaus Children’s Hospital
Coral Gables, FL

Linda Rogers, MD

Professor of Medicine
Icahn School of Medicine at Mt Sinai
Department of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
Clinical Director, Adult Asthma Program
Medical Director, Medicine Clinical Trials Office
New York, NY

Eileen Wang, MD, MPH

Associate Professor
Division of Allergy and Clinical Immunology
Department of Medicine
National Jewish Health
University of Colorado School of Medicine
Denver, Colorado

Michael E. Wechsler, MD, MMSc

Director, The Cohen Family Asthma Institute 
Professor of Medicine 
Division of Pulmonary, Critical Care, & Sleep Medicine 
National Jewish Health
Denver, CO

Conflicts of Interest Disclosure Policy

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty reports the following relevant financial relationship(s)

Miguel Lanz, MD, FAAAAI, FACAAI discloses the following relevant financial relationships:
Advisory Board: Amgen AstraZeneca, Genentech-Roche, Novartis, Sanofi Regeneron
Consultant: Amgen AstraZeneca, Chiesi
Speaker: Amgen AstraZeneca, Sanofi Regeneron
Investigator for studies funded by: Amgen AstraZeneca, Genentech-Roche, Sanofi Regeneron

Linda Rogers, MD discloses the following relevant financial relationships:
Advisory Board: AstraZeneca Pharmaceuticals, Sanofi
Consultant: AstraZeneca Pharmaceuticals, Regeneron, Sanofi
Investigator for studies funded by: Sanofi

Eileen Wang, MD, MPH discloses the following relevant financial relationships:
Advisory Board: AstraZeneca Pharmaceuticals, GlaxoSmithKline
Consultant: AstraZeneca Pharmaceuticals
Speaker: AstraZeneca Pharmaceuticals
Investigator for studies funded by: AstraZeneca Pharmaceuticals, Genentech, GlaxoSmithKline and Sanofi

Michael E. Wechsler, MD, MMSc discloses the following relevant financial relationships: Consultant/Advisory board:  AbbVie, Allakos, Amgen, Apogee, Areteia Therapeutics, Arrowhead Pharmaceutical, AstraZeneca, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Enveda Therapeutics, Equillium, General Medicines, Gilead, GlaxoSmithKline, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pfizer, Pharming, Phylaxis,  Pulmatrix, Rapt Therapeutics, Recludix Pharma, Regeneron, Roche/Genentech, Sanofi/Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Upstream Bio, Uniquity Bio, Verona Pharma, Zurabio.
Speaker: AstraZeneca, Amgen, Regeneron, GlaxoSmithKline, Sanofi/Genzyme
Investigator for studies funded by: AstraZeneca, Amgen, Regeneron, GlaxoSmithKline, Sanofi/Genzyme, Upstream Bio
Stock options: Cellergy Pharma Inc, Upstream Bio
 

Planners and reviewers report the following relationship(s)

Meghan Brenner, MA does not have any relevant financial relationships to disclose.

Laniecia Demmer does not have any relevant financial relationships to disclose

Andrea Harshman, MHA, CHCP, CMP-HC does not have any relevant financial relationships to disclose.

Harold Nelson, MD does not have any relevant financial relationships to disclose.

Unlabeled and Investigational Usage

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer Statement

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.